Cyclopropyl-{4-[2-(6-methyl-pyridin-2-yl)-imidazo[1,2-a]pyridin-3-yl]-pyrimidin-2-yl}-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: Cyclopropyl-{4-[2-(6-methyl-pyridin-2-yl)-imidazo[1,2-a]pyridin-3-yl]-pyrimidin-2-yl}-amine
• 英文别名: N-cyclopropyl-4-[2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridin-3-yl]pyrimidin-2-amine
• 化学式: C₂₀H₁₈N₆
• 分子量: 342.4
• InChiKey: BAFUGFTZYCDGRM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  68
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  3-(2-Methanesulfonyl-pyrimidin-4-yl)-2-(6-methyl-pyridin-2-yl)-imidazo[1,2-a]pyridine 、 环丙胺 在 acetonitrile-water 、 三氟乙酸 作用下， 以 乙腈 为溶剂， 反应 16.0h， 以to yield 40 mg of cyclopropyl-{4-[2-(6-methyl-pyridin-2-yl)-imidazo[1,2-a]pyridin-3-yl]-pyrimidin-2-yl}-amine as the TFA salt的产率得到Cyclopropyl-{4-[2-(6-methyl-pyridin-2-yl)-imidazo[1,2-a]pyridin-3-yl]-pyrimidin-2-yl}-amine
  参考文献：
  名称：

  Imidazolopyridines and methods of making and using the same

  摘要：

  公式I的化合物具有意外的高亲和力，可用作Alk 5和/或Alk 4的拮抗剂，以预防和/或治疗多种疾病，包括纤维化疾病。在一种实施例中，本发明涉及公式I的化合物：

  公开号：

  US20060135517A1

文献信息

• IMIDAZOLOPYRIDINES AND METHODS OF MAKING AND USING THE SAME
  申请人：Biogen Idec MA Inc.

  公开号：EP1546112A2

  公开（公告）日：2005-06-29
• EP1546112A4
  申请人：——

  公开号：EP1546112A4

  公开（公告）日：2006-06-07
• METHODS OF TREATING VASCULAR INJURIES
  申请人：Biogen Idec MA, Inc.

  公开号：EP1804801A2

  公开（公告）日：2007-07-11
• EFFICIENT INDUCTION OF PLURIPOTENT STEM CELLS USING SMALL MOLECULE COMPOUNDS
  申请人：Ichida Justin

  公开号：US20120021519A1

  公开（公告）日：2012-01-26

  The disclosure features a method of producing a reprogrammed cell (e.g. an induced pluripotent stem cell or an undifferentiated cell) from a differentiated (e.g. somatic) cell. In some embodiments, the methods includes contacting a differentiated (e.g. somatic cell) with a TGFBR1 inhibitor or anti-TGF-β-antibody to produce a reprogrammed cell (e.g. pluripotent stem cell or undifferentiated cell). Embodiments of the present invention relate to a reprogrammed cell and methods and compositions for producing a chemically produced reprogrammed cell or populations thereof.
• TGF-BETA RECEPTOR INHIBITORS TO ENHANCE DIRECT REPROGRAMMING
  申请人：THE GENERAL HOSPITAL CORPORATION

  公开号：US20140120621A1

  公开（公告）日：2014-05-01

  In general, iPS cells are produced by delivery of stem cell-associated genes into adult somatic cells (e.g., fibroblasts). Described herein are methods for enhancing the efficiency and rate of induced pluripotent stem cell production by treating somatic cells with a transforming growth factor-beta receptor (TGFβR) inhibitor. Also described herein are iPS cell compositions made according to the methods described herein and iPS cell compositions comprising an iPS cell in an admixture with a TGFβR inhibitor. Further described herein are kits for producing iPS cells using a TGFβR inhibitor.